ADVENTRX keeps Type A meeting with FDA to discuss Exelbine NDA ADVENTRX Pharmaceuticals.

ADVENTRX keeps Type A meeting with FDA to discuss Exelbine NDA ADVENTRX Pharmaceuticals, Inc. announced today that it kept a Type A gathering with the U.S canada pharmacy . Culley, Chief Executive Officer of ADVENTRX. The Agency’s evaluation of the medical data gives us confidence a repeat study would be successful and that Exelbine can be approved. Our money and equivalents of $40.at July 31 7 million, plus cost savings from discontinuing the Exelbine program, will provide us the administrative centre to advance both our ANX-188 and ANX-514 applications into their respective pivotal medical studies next year. Culley added. Several media reports condition Savage and her spouse plan to give the baby boy to his biological parents.